The first accelerated approval for a tumor-agnostic drug was granted by the FDA...
- Deals this week: AzurRx BioPharma, Innovent Biologics, Tosk
- M&As this week: Cosmos Holdings, Akebia Therapeutics, Biogen
- Deals this week: Adlai, Skyhawk, Aerpio Pharmaceuticals
- M&As this week: CSL Limited, Alliance Medical, Bio-Techne
- New drugs and therapeutic options help the immune system fight cancer
Deals this week: Idorsia, Assembly Biosciences, CytomX Therapeutics
Idorsia has raised Sfr200m ($202.1m) through a private placement of unsecured convertible bonds due 2024.
CIMZIA (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis
CIMZIA® (certolizumab pegol) is a subcutaneous infusion indicated for the treatment of adults with moderate-to-severe plaque psoriasis.
Upcoming Webinars for Malvern Panalytical
Malvern Panalytical has announced a wide range of upcoming webinars throughout July, including ‘Enter a New Dimension of X-Ray Diffraction Analysis’ and ‘Applications of Light Scattering and Intrinsic Viscosity Detectors with Size Exclusion Chromatography SEC in Characterising Biopharmaceutical and Other Polymers’. To register for any of these webinars, please either make an enquiry using the form on this page or visit www.malvernpanalytical.com/en/learn/events-and-training/webinars.
Lokelma (sodium zirconium cyclosilicate) for the Treatment of Adults with Hyperkalaemia
Lokelma is an oral suspension of sodium zirconium cyclosilicate that is indicated for the treatment of patients with hyperkalaemia.
Deals this week: AzurRx BioPharma, Innovent Biologics, Tosk
AzurRx BioPharma plans to raise $50m through a public offering of securities.
M&As this week: Cosmos Holdings, Akebia Therapeutics, Biogen
Cosmos Holdings has signed a share purchase agreement to acquire 100% interest in Cosmofarm Ltd (Cosmofarm) for an undisclosed sum.
Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection
Zepatier is a once-daily oral medicine comprising 50mg of non-structural protein 5A (NS5A) replication complex inhibitor elbasvir and 100mg of NS3/4A protease inhibitor grazoprevir.
Andexxa (andexanet alfa) for the Treatment of Factor Xa Inhibitor-Associated Acute Major Bleeding
Andexxa® (andexanet alfa) is an intravenous infusion indicated for the treatment of patients suffering from factor Xa (FXa) inhibitor-associated acute major bleeding.
Deals this week: Adlai, Skyhawk, Aerpio Pharmaceuticals
Adlai Nortye Biopharma has raised $50m through a series B financing round from Yuanming Capital.
M&As this week: CSL Limited, Alliance Medical, Bio-Techne
CSL Limited has signed an agreement to purchase the remaining 20% interest in Wuhan Zhong Yuan Rui De Biological Products (Ruide) from Humanwell Healthcare Group for $102m.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.